Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gossamer Bio Inc. (GOSS:NASDAQ), powered by AI.
Gossamer Bio Inc. is currently trading at $0.21. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Gossamer Bio Inc. on Alpha Lenz.
Gossamer Bio Inc.'s P/E ratio is -0.3.
“Gossamer Bio Inc. trades at a P/E of -0.3 (undervalued) with strong ROE of 365.3%.”
Ask for details →Gossamer Bio Inc. is a biopharmaceutical company dedicated to discovering and developing innovative therapies for patients with unmet medical needs. Its primary focus is on immunology and inflammation, aiming to address serious pathologies within these areas. Gossamer Bio serves critical sectors such as autoimmune diseases, allergy responses, and oncology, through leveraging its advanced understanding of immune system mechanisms. This San Diego-based company develops a robust pipeline of product candidates across various stages of clinical trials, underscoring its commitment to advancing transformative therapies. In the financial market, Gossamer Bio plays an essential role by contributing to medical innovation, offering potential breakthroughs that significantly impact patient care and healthcare systems. Their work supports broader industry objectives by striving to bring novel drugs to market, thereby potentially transforming disease management. As a biopharmaceutical entity, Gossamer Bio Inc. represents the confluence of cutting-edge science and patient-centric focus, solidifying its strategic importance within the healthcare investment and development sectors.
“Gossamer Bio Inc. trades at a P/E of -0.3 (undervalued) with strong ROE of 365.3%.”
Ask for details →Gossamer Bio Inc. (ticker: GOSS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 144 employees. Market cap is $45M.
The current price is $0.211 with a P/E ratio of -0.27x and P/B of -0.37x.
ROE is 365.33% and operating margin is -336.81%. Annual revenue is $48M.